- March 30, 2023
George Mason University researchers are taking advantage of DNA molecules’ self-assembly properties to develop vaccines rapidly, publishing their findings in Communications Biology
- Mason’s Michael Buschmann and team at start-up AexeRNA Therapeutics Inc. pursue patents for improved COVID-19 vaccinesJuly 28, 2021
Mason's Michael Buschmann and his team have developed technology that could help make COVID-19 vaccines less costly, with fewer side-effects and more available.
- Tue, 03/10/2020 - 17:45